Meeting an Aggressive Go-To-Clinic Timeline
ADARE PHARMA SOLUTIONS SPONSORED CONTENT

Meeting an Aggressive Go-To-Clinic Timeline

A mid-sized pharma company was working with a very large CDMO to enter clinical trials for a potentially life-changing medication that may slow the progression of common neurodegenerative disorders. However, the large CDMO lacked resourcefulness and delayed production of the clinical trial batches for months. The company’s go-to-clinic timelines were already aggressive, and this delay from their CDMO jeopardized their market commitments for the start of Phase 2 and 3 clinical trials.

When the large CDMO couldn’t give the pharma company the proper attention, Adare stepped in to get their project to the clinic quickly. This case study shows the ways that, by partnering with Adare, the pharma company was able to provide its clinical trials with the supplies needed to be conducted successfully. Download now to learn more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.